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Background: Breast cancer is the most common malignant disease in women. The patients with advanced breast cancer develop metastasis 
to bone. Bone metastasis and skeletal-related events by breast cancer are frequently associated with the invasiveness of breast cancer 
cells and osteoclasts-mediated bone resorption. Forsythia koreana is used in oriental traditional medicine to treat asthma, atopy, and 
allergic diseases. The aim of this study was to evaluate the inhibitory effects of F. koreana extracts on the invasion of breast cancer 
cells and bone resorption by osteoclasts.
Methods: Cell viability was measured by an MTT assay and the migration and invasion of MDA-MB-231 cells were detected by a Boyden 
chamber assay. The formation of osteoclasts and pit was detected using tartrate-resistant acid phosphatase staining and calcium  
phosphate-coated plates, respectively. The activities of matrix metalloproteinases (MMPs) and cathepsin K were evaluated by gelatin 
zymography and a cathepsin K detection kit.
Results: The fruit and leaf extracts of F. koreana significantly inhibited the invasion of MDA-MB-231 cells at noncytotoxic concentrations. 
The fruit extract of F. koreana reduced the transforming growth factor 1-induced migration, invasion and MMPs activities of MDA-MB-231 
cells. In addition, the fruit, branch, and leaf extracts of F. koreana also inhibited the receptor activator of nuclear factor kappa-B 
ligand-induced osteoclast formation and osteoclast-mediated bone-resorbing activity by reducing the activities of MMPs and cathepsin 
K.
Conclusions: The extracts of F. koreana may possess the potential to inhibit the breast cancer-induced bone destruction through blocking 
invasion of breast cancer cells, osteoclastogenesis, and the activity of mature osteoclasts.
(J Cancer Prev 2016;21:88-94)
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INTRODUCTION
Bone metastasis frequently occurs in patients with metastatic 
breast cancer.1 Bone microenvironment is suitable for breast 
cancer metastasis because of various growth factors in bone 
matrix such as insulin-like factors, TGF-, fibroblast growth 
factors, platelet-derived growth factors, and bone morphogenetic 
proteins.2,3 In normal bone, there is balance between osteoclasts 
which resorb bone and osteoblasts which form bone. Metastatic 
breast cancer cells secrete osteolytic factors, including parathyroid 
hormone-related protein, interleukin (IL)-6, IL-8, and IL-11.4 
These factors stimulate osteoblasts or stromal cells to produce 
receptor activator of nuclear factor kappa-B ligand (RANKL) and 
inhibit decoy receptor osteoprotegerin. RANKL binds to RANK of 
osteoclasts precursors and induces osteoclast differentiation, 
causing bone resorption.5,6 The growth factors are released from 
bone matrix by bone resorption and promote breast cancer cell 
proliferation and secretion of osteolytic factors.7,8 Therefore, 
osteoclasts, as well as breast cancer cells, can be a strategic thera-
peutic target for breast cancer patients with bone metastasis.9,10
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Traditional medicine plants are being considered as pro-
mising research materials in drug discovery.11 Forsythia koreana, 
a flowering plant in the family Oleaceae, is widely cultivated in 
South Korea and used to treat inflammatory diseases in Chinese 
medicine.12 F. koreana extract has various pharmacological 
properties including antioxidant, anti-bacterial, and anti-allergic 
activities.13-15 In particular, F. koreana fruit extract inhibits 
COX-2-mediated prostaglandin E2 production and nitric oxide 
synthase, indicating anti-inflammatory effects.16,17 Recent stu-
dies reported that the bioactive compounds from F. koreana fruit 
extract have cytotoxicity against Michigan Cancer Foundation 
(MCF)-7 human non-metastatic breast cancer cells via activation 
of caspase-8 and induction of the DR4/5 death receptors.18 
However, the effect of F. koreana extracts on metastatic breast 
cancer cells and osteoclasts, which are target cells for blocking 
cancer-induced bone destruction, remains unproved.
The aim of this study is to evaluate the protective potential of 
F. koreana extracts on breast cancer cell-induced bone destru-
ction. We investigated the effects of F. koreana extracts on the 
migration and invasion of breast cancer cells and the formation 
and activation of osteoclasts.
MATERIALS AND METHODS
1. Materials
F. koreana Nakai branches and leaves were extracted with 
methanol and concentrated. Fruit extract was provided by Korea 
National Research Resource Bank. The extracts were dissolved 
with dimethyl sulfoxide (DMSO). Dulbecco’s modified Eagle 
medium (DMEM), FBS, Dulbecco’s PBS, -minimum essential 
medium (-MEM), and antibiotics were purchased from Gibco BRL 
(Grand Island, NY, USA). Recombinant mouse soluble RANKL 
(sRANKL) and macrophage-colony stimulating factor (M-CSF) 
were obtained from R&D Systems (Minneapolis, MN, USA). 
Histopaque-1083, MTT, DMSO were purchased from 
Sigma-Aldrich (St. Louis, MO, USA).
2. Animal
Four-week old male Institute of Cancer Research (ICR) mice 
were purchased from the Nara Biotech (Pyeongtaek, Korea). The 
mice were provided free access to a commercial rodent chow and 
tap water ad libritum, and housed under specific pathogen-free 
conditions with a 12 hours light/dark cycle at 22oC ± 2oC. All 
animal experimental procedures were conducted in com-
pliance with the guidelines and regulations for the use and 
care of animals established by Yonsei University College of 
Dentistry (Seoul, Korea). 
3. Cell cultures
Human mammary carcinoma cell line MDA-MB-231 was 
obtained from the Korea Cell Line Bank (Seoul, Korea) and the 
cells were maintained in DMEM supplemented with 10% FBS 
and 1% antibiotic-antimycotic mixture at 37oC. Mouse bone 
marrow-derived macrophages (BMMs) were isolated from tibiae 
of 4-week-old male ICR mice and cultured in a -MEM containing 
10% FBS, 30 ng/mL M-CSF, and 1% antibiotic-antimycotic mixture 
at 37oC. All of the cells were incubated in a humidified atmo-
sphere of 5% CO2.
4. Cell viability
MDA-MB-231 cells (1 × 103 cells/well) were seeded into a 
96-well plate with DMEM containing 10% FBS and the attached 
cells were incubated in serum-free media with the various 
concentrations of F. koreana fruit, branch or leaf extract for 24 
hours. BMM cells (5 × 104 cells) were treated with the indicated 
concentration of F. koreana fruit, branch or leaf extract in -MEM 
containing 10% FBS and 30 ng/mL M-CSF for 5 days with 
replacement to fresh medium every second day. The cell viability 
was measured using an MTT assay.19
5. Cell migration and invasion
Migration assay was performed in 24-well transwell chamber 
(8 mm pore size; Corning Costar, Cambridge, MA, USA) coated 
with 10% (w/v) gelatin. Invasion assay was performed using 24-well 
transwell chamber coated with 10% (w/v) gelatin and 1 mg/mL 
Matrigel (BD Biosciences, Palo Alto, CA, USA). MDA-MB-231 cells 
(5 × 104 cells/200 L) were incubated in serum-free DMEM 
containing F. koreana fruit extract at the indicated concentrations 
and/or TGF-1 (10 ng/mL) in the upper part of a transwell 
chamber for 6 hours or 24 hours. The lower part of chamber were 
added with 600 L DMEM containing 5% FBS and F. koreana fruit 
extract at the indicated concentrations. The migrated or invaded 
cells to the lower surface of the membrane were fixed with 70% 
methanol, stained with hematoxylin, and then counted using a 
Zeiss Axio imager microscope (Zeiss, Oberkochen, Germany).
6. Osteoclast formation
BMMs (5 × 104 cells/well) were seeded in 96-well plate and 
cultured with -MEM containing 10% FBS, M-CSF (30 ng/mL), 
sRANKL (100 ng/mL), and the various concentrations of F. 
koreana extracts for 5 days. The medium was replaced with fresh 
medium every 2 days. The cells were fixed with 3.7% (v/v) 
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Figure 1. The effects of Forsythia koreana extracts on the viability and invasion 
of MDA-MB-231 cells. MDA-MB-231 cells were treated with indicated concentrations 
of F. koreana (A) fruit, (B) branch, and (C) leaf extracts for 24 hours. The cell via-
bility was determined by an MTT assay. (D) MDA-MB-231 cells were placed on the 
Matrigel-coated upper chambers with serum-free Dulbecco’s modified Eagle medium 
(DMEM) containing F. koreana extracts. The lower chambers were filled with 600 L
of 5% FBS-DMEM and F. koreana extracts. Twenty-four hours later, the invaded cells 
were counted. Data are expressed mean ± SE. *P ＜ 0.05, **P ＜ 0.01 vs. untreated 
cells.
formaldehyde and stained using the Acid Phosphatase Leukocyte 
kit (Sigma-Aldrich). The multinucleated tartrate-resistant acid 
phosphatase-positive cells (≥ 3 nuclei) were counted (× 100, 
magnification).
7. Pit formation 
BMMs (5 × 104 cells/well) were seeded in an Osteo assay plate 
(Corning, Cambridge, MA, USA) and cultured in -MEM 
containing 10% FBS, M-CSF (30 ng/mL), and sRANKL (100 ng/mL) 
for 5 days to induce osteoclastogenesis. The cells were then 
treated with the various concentrations of F. koreana extracts for 
additional 2 days. The media were collected to measure the 
activities of MMPs and cathepsin K and the adherent cells were 
removed using 5% sodium hypochlorite solution. The resorbed 
pits were observed under light microscope (× 100, 
magnification).
8. Activities of matrix metalloproteinases and 
cathepsin K
MDA-MB-231 cells (5 × 105 cells/dish) were plated in 60 mm 
culture dishes and incubated with indicated concentrations of F. 
koreana fruit extract in DMEM containing 1% FBS and TGF-1 (10 
ng/mL) for 24 hours. The culture media of MDA-MB-231 cells and 
RANKL-induced osteolcasts were collected by centrifugation at 
200 ×g for 5 minutes. The activities of MMP-2 and MMP-9 were 
detected by gelatin zymography and cathepsin K activity was 
measured with commercially available kit as described previ-
ously.20
9. Statistics analysis
Data were expressed as mean ± SE of three independent 
experiments. Statistical analysis was performed with a one-way 
ANOVA and Student’s t-test to express the difference between the 
two groups. Results with values of P ＜ 0.05 were considered 
statistically significant. Statistical analysis was performed with 
SPSS statistical software ver. 21 (IBM Co., Endicott, NY, USA).
RESULTS
1. Forsythia koreana extracts inhibited the invasion 
of MDA-MB-231 human breast cancer cells
We first investigated the effects of F. koreana fruit, branch, and 
leaf extracts on the viability of MDA-MB-231 metastatic human 
breast cancer cells. The fruit extract inhibited the cell viability by 
15% at 40 g/mL and by 33% at 100 g/mL (Fig. 1A) but the branch 
(Fig. 1B) and leaf (Fig. 1C) extracts did not affect. Next, we found 
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Figure 2. The effects of Forsythia koreana fruit extract on 
TGF-1-induced migration and invasion of MDA-MB-231 cells. (A) 
MDA-MB-231 cells were placed on the upper chambers with se-
rum-free Dulbecco’s modified Eagle medium (DMEM) containing F. 
koreana fruit extract and TGF-1 (10 ng/mL). The lower chambers 
were filled with 600 L of 5% FBS-DMEM containing F. koreana fruit 
extract. The cells were incubated for 6 hours. (B) MDA-MB-231 cells 
were placed on the Matrigel-coated upper chambers with serum-free 
DMEM containing F. koreana fruit extract and TGF-1 (10 ng/mL). 
The lower chambers were filled with 600 L of 5% FBS-DMEM con-
taining F. koreana fruit extracts. The cells were incubated for 24 
hours. The migrated or invaded cells were fixed, stained, and count-
ed as a described in Materials and Methods. Data are expressed 
mean ± SE. #P ＜ 0.05, ##P ＜ 0.01 vs. untreated cells, *P ＜ 0.05, 
**P ＜ 0.01 vs. MDA-MB-231 cells with TGF-1 alone. (C) 
MDA-MB-231 cells were cultured with F. koreana fruit extract and 
1% FBS-DMEM in the absence or presence of TGF-1 (10 ng/mL) for 
24 hours. The levels of matrix metalloproteinase (MMP)-2 and 
MMP-9 in the collected medium were examined using gelatin 
zymography. The clear bands indicate the activities of MMPs.
that F. koreana fruit and leaf extracts significantly reduced the 
invasion of MDA-MB-231 cells by 48% and 41% at 20 g/mL and 
84% and 58% at 40 g/mL, respectively (Fig. 1D).
2. Forsythia koreana fruit extract attenuated the 
TGF-1-induced migration and invasion of MDA- 
MB-231 cells
TGF-1 plays a critical role in the migration and invasion of 
breast cancer cells.21,22 MMPs are closely associated with cancer 
invasion and metastasis.23 The treatment with F. koreana fruit 
extract decreased the migration (IC50 = 50.6 g/mL; Fig. 2A) and 
invasion (IC50 = 22.5 g/mL; Fig. 2B) of MDA-MB-231 cells by 75% 
and 92% at 80 g/mL, respectively. TGF-1-induced migration 
(IC50 = 49.5 g/mL; Fig. 2A) and invasion (IC50 = 40.9 g/mL; Fig. 
2B) were also reduced by F. koreana fruit extract by 79% and 82% 
at 80 g/mL, respectively. In addition, the fruit extract suppressed 
the proteolytic activities of MMP-2 and MMP-9 in the culture 
media of MDA-MB-231 cells with or without TGF-1 (Fig. 2C).
3. Forsythia koreana extracts blocked the receptor 
activator of nuclear factor kappa-B ligand-induced 
osteoclast formation
Bone loss induced by metastasis of breast cancer is caused by 
excessive osteoclasts.5 The viability of BMMs as osteoclast 
precursors was not reduced by the treatment with F. koreana fruit 
(Fig. 3A), branch (Fig. 3B) or leaf (Fig. 3C) extracts for 5 days. 
RANKL-induced osteoclast formation was significantly decreased 
by 24%, 58%, and 92% at 10 g/mL and 79%, 95%, and 100% at 20 
g/mL of the fruit, branch, and leaf extracts, respectively (Fig. 3D).
4. Forsythia koreana extracts suppressed the bone- 
resorbing activity of mature osteoclasts
In bone mimetic material-coated plates, three F. koreana 
extracts substantially inhibited the formation of osteoclast-me-
diated resorption pits (Fig. 4A). In gelatin zymography, F. koreana 
branch extract suppressed the activities of MMP-2 and MMP-9 
derived from RANKL-induced osteoclasts but the fruit and leaf 
extracts did not show noticeable inhibition (Fig. 4B). In addition, 
the cathepsin K activities induced by RANKL stimulation were 
significantly decreased by the treatment with F. koreana fruit, 
branch, and leaf extracts by 67%, 80%, and 78% at 40 g/mL, 
respectively (Fig. 4C).
DISCUSSION
In the present study to investigate whether F. koreana extracts 
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Figure 3. The effects of Forsythia koreana extracts on receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclast formation. 
The bone marrow-derived macrophages (BMMs) were treated with M-CSF (30 ng/mL) and indicated concentrations of F. koreana (A) fruit, (B) 
branch, or (C) leaf extracts for 5 days. The cell viability was determined by an MTT assay. Data are expressed as the mean ± SE. *P ＜ 0.05,
**P ＜ 0.001 vs. untreated cells. (D) The BMMs were cultured in -minimum essential medium with M-CSF (30 ng/mL), RANKL (100 ng/mL) and 
F. koreana extracts at the indicated concentrations for 5 days. The cells were detected by tartrate-resistant acid phosphatase staining and osteo-
clasts were counted (× 100, magnification). Data are expressed as the mean ± SE. #P ＜ 0.05 vs. BMMs without RANKL (C, control). *P ＜
0.05, **P ＜ 0.001 vs. BMMs with RANKL alone.
have preventive potential on breast cancer-induced bone dest-
ruction, F. koreana fruit extract suppressed the viability of 
MDA-MB-231 metastatic breast cancer cells but did not show high 
cytotoxic effect. The fruit and leaf extracts at the non-cytotoxic 
concentrations considerably inhibited the invasiveness of 
MDA-MB-231 cells. Cancer cells interact with many growth factors 
and cytokines during progression and metastasis.24,25 Among 
them, TGF-1 enhances the metastatic ability of breast cancer 
cells through stimulation of epithelial-mesenchymal transition 
processes and the activation of the MMPs, which are required for 
cancer cells to degrade physical barriers during local expansion, 
intravasation, extravasation, and invasion at a distant location.8,26 
TGF-1 modulates the homeostasis between MMPs and MMP 
inhibitors in highly invasive breast cancer cells.27 In our data, F. 
koreana fruit extract, with weak cytotoxic activity but remarkable 
anti-invasive activity in MDA-MB-231 cells, inhibited TGF-1-in-
duced migration, invasion, and activities of MMP-2 and MMP-9. 
These results demonstrate the anti-metastatic potential of F. 
koreana fruit extract against metastatic breast cancer cells.
In breast cancer patients with bone metastasis, osteoclast 
formation, and activation were abnormally increased.2 Several 
enzymes such as cathepsin K and MMPs were released from 
mature osteoclasts and these hydrolytic enzymes digest organic 
components of the bone matrix and promote bone resorption.28 
Thus, many researchers have paid much attention to osteocl-
ast-targeting new agents for the treatment of patients with bone 
metastasis of breast cancer.9,10 Recent studies suggest that breast 
cancer induced-bone destruction can be prevented by controlling 
RANKL-induced osteoclast formation and activities of these 
enzymes.20,29-31 In our study, F. koreana fruit, branch, and leaf 
extracts did not show cytotoxicity at less than 100 g/mL and 
significantly inhibited the RANKL-induced formation of osteoclasts 
 Yu Li Kim, et al: Effects of F. koreana on Breast Cancer and Bone Resorption 93
Figure 4. The effects of Forsythia koreana extracts on bone resorbing-activity of osteoclasts. Bone marrow-derived macrophages (BMMs) were 
seeded in Osteo assay plate and treated with M-CSF (30 ng/mL) and receptor activator of nuclear factor kappa-B ligand (RANKL) (100 ng/mL) 
for 5 days. After induction of osteoclasts, the cells were treated with F. koreana extracts for an additional 2 days. (A) The resorption pits 
were observed under a light microscopy (× 100, magnification). (B) The activities of matrix metalloproteinase (MMP)-2 and MMP-9 in cultured
media of osteoclasts were detected by gelatin zymography as described in Materials and Methods. (C) Cathepsin K levels in cultured media 
of osteoclasts were measured using the Sensizyme Cathepsin K activity kit. Data are expressed as the mean ± SE. #P ＜ 0.05 vs. BMMs 
without RANKL (C, control). *P ＜ 0.05, **P ＜ 0.001 vs. BMMs with RANKL alone.
and resorption pits at 20 g/mL. Moreover, F. koreana branch 
extract, rather than the fruit and leaf extracts, substantially 
inhibited the secreted levels of MMP-2 and MMP-9. Three 
extracts decreased the release of osteoclast-derived cathepsin K 
into the culture media. These results indicate that F. koreana 
extracts may prevent breast cancer-related bone resorption by 
attenuating RANKL-induced osteoclast formation and activation.
Taken together, F. koreana fruit and leaf extracts have anti-me-
tastatic potential on breast cancer cells and F. koreana extracts 
have anti-osteoclastogenic and anti-bone-resorbing activities. 
Therefore, F. koreana extracts can target both breast cancer cells 
and osteoclasts, thereby they may be promising agents for pre-
vention of cancer-mediated bone loss and the related skeletal 
diseases.
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